MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-20-2026
Abbott Laboratories Accounts Payables 2011-2026 | ABT
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Abbott Laboratories
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.24 B | 4.2 B | 4.3 B | 4.61 B | 4.41 B | 3.95 B | 3.25 B | 2.98 B | 2.4 B | 1.18 B | 1.08 B | 1.06 B | 1.03 B | 1.8 B | 1.72 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.61 B | 1.03 B | 2.81 B |
Quarterly Accounts Payables Abbott Laboratories
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.31 B | 4.21 B | 4.03 B | 4.12 B | 4.18 B | 3.96 B | 4.21 B | 4.17 B | 4.61 B | 4.13 B | - | 4.76 B | 4.41 B | 4.02 B | 4.02 B | 4.07 B | 3.95 B | 3.95 B | 3.95 B | 3.95 B | 3.25 B | 3.25 B | 3.25 B | 3.25 B | 2.98 B | 2.98 B | 2.98 B | 2.98 B | 2.4 B | 2.4 B | 2.4 B | 2.4 B | 1.18 B | 1.18 B | 1.18 B | 1.18 B | 1.08 B | 1.08 B | 1.08 B | 1.08 B | 1.06 B | 1.06 B | 1.06 B | 1.06 B | 1.03 B | 1.03 B | 1.03 B | 1.03 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.72 B | 1.72 B | 1.72 B | 1.72 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.76 B | 1.03 B | 2.64 B |
Accounts Payables of other stocks in the Medical devices industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Sensus Healthcare
SRTS
|
1.2 M | $ 4.1 | -2.96 % | $ 66.9 M |  USA |
 |
Axonics Modulation Technologies
AXNX
|
9.07 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
4.79 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
2.76 M | - | -26.83 % | $ 2.62 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
82.5 M | $ 9.86 | 3.25 % | $ 759 M | USA |
 |
Allied Healthcare Products
AHPI
|
1.21 M | - | 3.58 % | $ 2.21 M | USA |
 |
Conformis
CFMS
|
4.16 M | - | - | $ 16.4 M | USA |
 |
Delcath Systems
DCTH
|
2.66 M | $ 9.18 | -0.22 % | $ 329 M | USA |
 |
Stryker Corporation
SYK
|
1.8 B | $ 335.31 | 2.37 % | $ 128 B | USA |
 |
Dynatronics Corporation
DYNT
|
3.4 M | - | 14.99 % | $ 929 K | USA |
 |
Cardiovascular Systems
CSII
|
14.4 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
817 K | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
7.42 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
777 K | - | -20.74 % | $ 369 K | USA |
 |
TELA Bio
TELA
|
2.31 M | $ 0.71 | 3.13 % | $ 33.3 M | USA |
 |
CONMED Corporation
CNMD
|
93.6 M | $ 36.91 | -0.32 % | $ 1.15 B | USA |
 |
Insulet Corporation
PODD
|
75 M | $ 220.63 | 2.14 % | $ 15.5 B | USA |
 |
Tandem Diabetes Care
TNDM
|
47.1 M | $ 23.46 | -3.32 % | $ 1.6 B | USA |
 |
Electromed
ELMD
|
2.67 M | $ 24.74 | 0.32 % | $ 209 M | USA |
 |
Cytosorbents Corporation
CTSO
|
3.34 M | $ 0.62 | -8.39 % | $ 33.7 M | USA |
 |
Aethlon Medical
AEMD
|
535 K | $ 2.37 | 2.22 % | $ 3.7 M | USA |
 |
BIOLASE
BIOL
|
6.06 M | - | -13.19 % | $ 166 K | USA |
 |
LivaNova PLC
LIVN
|
97.2 M | $ 64.75 | 2.28 % | $ 3.53 B |  Britain |
 |
InspireMD
NSPR
|
1.26 M | $ 1.74 | -0.57 % | $ 112 M |  Israel |
 |
AdaptHealth Corp.
AHCO
|
352 M | $ 11.6 | 1.84 % | $ 1.57 B | USA |
 |
Penumbra
PEN
|
34.7 M | $ 337.13 | 0.26 % | $ 13.1 B | USA |
 |
MiMedx Group
MDXG
|
14.5 M | $ 4.08 | -0.49 % | $ 603 M | USA |
 |
Invacare Corporation
IVC
|
105 M | - | - | $ 24.7 M | USA |
 |
Viemed Healthcare
VMD
|
7.33 M | $ 9.32 | -0.32 % | $ 363 M | USA |
 |
Myomo
MYO
|
1.51 M | $ 0.69 | -1.61 % | $ 28.9 M | USA |
 |
NanoVibronix
NAOV
|
47 K | - | - | $ 1.08 M | USA |
 |
Varex Imaging Corporation
VREX
|
69.9 M | $ 10.72 | 0.28 % | $ 444 M | USA |
 |
Vivos Therapeutics
VVOS
|
1.1 M | $ 1.24 | 7.37 % | $ 6.22 M | USA |
 |
Inspire Medical Systems
INSP
|
36.6 M | $ 51.41 | - | $ 1.51 B | USA |
 |
Pulmonx Corporation
LUNG
|
3.9 M | $ 1.29 | -1.15 % | $ 52.5 M | USA |
 |
Beyond Air
XAIR
|
1.95 M | $ 0.74 | 0.01 % | $ 50.1 M | USA |
 |
Xtant Medical Holdings
XTNT
|
7.92 M | $ 0.57 | 0.85 % | $ 76.2 M | USA |